Additionally, after evaluating how CVD risk changes over time in men with type 2 diabetes and PCa treated with GnRH agonists as well as the association between metabolic risk factors for CVD risk and use of GnRH agonists, we propose that future research needs to further identify the proportion of indirect effects of these metabolic risk factors through GnRH agonists in men with type 2 diabetes by mediation analysis. This evidence concerns the gene GNRH1 and posterior cortical atrophy.